GlassScriptPhysician profile
Snezana Radnovic
NPI 1073910618
$11,278.63
in general payments reported to CMS, 2019-2025
24 companies · $3,086 in 2025
The $3,086 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $665 · 2022: $1,962 · 2023: $2,493 · 2024: $3,073 · 2025: $3,086.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,562 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,562.09 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,886.74 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $1,522.65 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,320.71 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,238.58 | 2022-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $1,074.34 | 2022-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Neurocrine Biosciences, INC. | $852.49 | 2021-2024 | Ingrezza |
| Axsome Therapeutics, INC. | $618.29 | 2023-2025 | Auvelity |
| Alkermes, INC. | $578.35 | 2022-2025 | Lybalvi |
| Vanda Pharmaceuticals INC. | $499.94 | 2024-2025 | Fanapt |
| Idorsia Pharmaceuticals US INC | $367.88 | 2022-2024 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $363.47 | 2024-2025 | Cobenfy |
| Corium, LLC | $180.36 | 2022-2024 | Azstarys |
| Neos Therapeutics, LP | $131.95 | 2024 | Adzenys Xr-Odt |
| Supernus Pharmaceuticals, INC. | $129.79 | 2023 | Qelbree |
| Genzyme Corporation | $119.70 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $119.00 | 2024-2025 | |
| Becton, Dickinson and Company | $89.00 | 2023-2024 | Bd Phaseal |
| Baudax Bio INC. | $59.19 | 2021-2022 | |
| Almatica Pharma LLC | $27.06 | 2024 | Loreev Xr |
| Bausch & Lomb Americas INC. | $24.98 | 2025 | Stellaris |
| Takeda Pharmaceuticals U.S.A., INC. | $20.38 | 2024 | Trintellix |
| Janssen Scientific Affairs, LLC | $19.66 | 2024 | Spravato |
| Acacia Pharma INC | $18.12 | 2021 | |
| Bard Peripheral Vascular, INC. | $16.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Snezana Radnovic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.